Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2002

View Archived Issues

U.S. launch of new injectable carbapenem announced by Merck

Bextra now available for prescription in the U.S.

Evidence of antipsoriatic activity obtained in phase II trial of topical alicaforsen

Newly introduced Elidel cream associated with reduced disease flares and corticosteroid use

Xanelim pivotal results discussed at the AAD meeting; BLA may be filed this summer

Novel class of analgesics --VR1 blockers-- discovered by Spanish researchers

IL-6 exerts central antiobesity effects in rodents

Cubist and Novartis extend antiinfective drug discovery collaboration

Caprion and McGill University to collaborate on proteomics research

FlowGuard approved in U.S.

NDA filed for acamprosate for the treatment of alcohol dependency

Initiation of phase II trial of MVA-HPV-IL-2 in cervical intraepithelial neoplasia

FDA approves new indication for Plavix in acute coronary syndrome

Schering initiates phase III BENEFIT study of Betaferon/Betaseron

MS-818 accelerates early muscle regeneration and enhances recovery postsurgery

ImClone and partners discuss resubmission of Erbitux BLA with FDA

Access acquires targeted therapeutic division of Biotech Australia

Once- or twice-yearly i.v. zoledronic acid effective in postmenopausal osteoporosis

Tissue-specific selfinactivating gene therapy described by UAB Research Foundation

Ranbaxy designs compounds effective against Gram-positive and anaerobic bacteria

Compounds with high affinity for the alpha5 subunit of GABA-A receptors

Phosphate esters of peptidomimetic compounds for treatment of HIV infection

American Cyanamid prepares new inhibitors of TACE and other MMPs

Inhibitors of factor Xa with utility in thrombosis associated with cardiovascular disorders

DuPont discloses compounds for the treatment of anxiety and depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...